Gene Therapy vs CAR-T (Solid Tumor) — Oncology Deal Terms Comparison
Market Analysis
In oncology, Gene Therapy and CAR-T (Solid Tumor) represent two of the most actively transacted modalities. At Phase 2, Gene Therapy deals carry a median total deal value of $1.6B with $253M upfront, compared to $2.3B total value and $356M upfront for CAR-T (Solid Tumor). The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Gene Therapy development milestones average $338M versus $484M for CAR-T (Solid Tumor). Commercial milestones are $473M for Gene Therapy and $678M for CAR-T (Solid Tumor). Royalty rates range from 11.7%-19.2% for Gene Therapy and 13%-21.3% for CAR-T (Solid Tumor).
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Gene Therapy and CAR-T (Solid Tumor) deal terms compare in oncology?
Which modality commands higher royalty rates: Gene Therapy or CAR-T (Solid Tumor)?
How do milestone structures differ between Gene Therapy and CAR-T (Solid Tumor)?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.